Your browser doesn't support javascript.
loading
SARS-CoV-2 Omicron Spike recognition by plasma from individuals receiving BNT162b2 mRNA vaccination with a 16-week interval between doses.
Chatterjee, Debashree; Tauzin, Alexandra; Marchitto, Lorie; Gong, Shang Yu; Boutin, Marianne; Bourassa, Catherine; Beaudoin-Bussières, Guillaume; Bo, Yuxia; Ding, Shilei; Laumaea, Annemarie; Vézina, Dani; Perreault, Josée; Gokool, Laurie; Morrisseau, Chantal; Arlotto, Pascale; Fournier, Éric; Guilbault, Aurélie; Delisle, Benjamin; Levade, Inès; Goyette, Guillaume; Gendron-Lepage, Gabrielle; Medjahed, Halima; De Serres, Gaston; Tremblay, Cécile; Martel-Laferrière, Valérie; Kaufmann, Daniel E; Bazin, Renée; Prévost, Jérémie; Moreira, Sandrine; Richard, Jonathan; Côté, Marceline; Finzi, Andrés.
Afiliación
  • Chatterjee D; Centre de Recherche du CHUM, Montreal, QC H2X 0A9, Canada.
  • Tauzin A; Centre de Recherche du CHUM, Montreal, QC H2X 0A9, Canada; Département de Microbiologie, Infectiologie et Immunologie, Université de Montréal, Montreal, QC H2X 0A9, Canada.
  • Marchitto L; Centre de Recherche du CHUM, Montreal, QC H2X 0A9, Canada; Département de Microbiologie, Infectiologie et Immunologie, Université de Montréal, Montreal, QC H2X 0A9, Canada.
  • Gong SY; Centre de Recherche du CHUM, Montreal, QC H2X 0A9, Canada; Department of Microbiology and Immunology, McGill University, Montreal, QC H3A 2B4, Canada.
  • Boutin M; Centre de Recherche du CHUM, Montreal, QC H2X 0A9, Canada; Département de Microbiologie, Infectiologie et Immunologie, Université de Montréal, Montreal, QC H2X 0A9, Canada.
  • Bourassa C; Centre de Recherche du CHUM, Montreal, QC H2X 0A9, Canada.
  • Beaudoin-Bussières G; Centre de Recherche du CHUM, Montreal, QC H2X 0A9, Canada; Département de Microbiologie, Infectiologie et Immunologie, Université de Montréal, Montreal, QC H2X 0A9, Canada.
  • Bo Y; Department of Biochemistry, Microbiology and Immunology, Center for Infection, Immunity, and Inflammation, University of Ottawa, Ottawa, ON K1H 8M5, Canada.
  • Ding S; Centre de Recherche du CHUM, Montreal, QC H2X 0A9, Canada.
  • Laumaea A; Centre de Recherche du CHUM, Montreal, QC H2X 0A9, Canada; Département de Microbiologie, Infectiologie et Immunologie, Université de Montréal, Montreal, QC H2X 0A9, Canada.
  • Vézina D; Centre de Recherche du CHUM, Montreal, QC H2X 0A9, Canada; Département de Microbiologie, Infectiologie et Immunologie, Université de Montréal, Montreal, QC H2X 0A9, Canada.
  • Perreault J; Héma-Québec, Affaires Médicales et Innovation, Quebec, QC G1V 5C3, Canada.
  • Gokool L; Centre de Recherche du CHUM, Montreal, QC H2X 0A9, Canada.
  • Morrisseau C; Centre de Recherche du CHUM, Montreal, QC H2X 0A9, Canada.
  • Arlotto P; Centre de Recherche du CHUM, Montreal, QC H2X 0A9, Canada.
  • Fournier É; Laboratoire de Santé Publique du Québec, Institut Nationale de Santé Publique du Québec, Sainte-Anne-de-Bellevue, QC H9X 3R5, Canada.
  • Guilbault A; Laboratoire de Santé Publique du Québec, Institut Nationale de Santé Publique du Québec, Sainte-Anne-de-Bellevue, QC H9X 3R5, Canada.
  • Delisle B; Laboratoire de Santé Publique du Québec, Institut Nationale de Santé Publique du Québec, Sainte-Anne-de-Bellevue, QC H9X 3R5, Canada.
  • Levade I; Laboratoire de Santé Publique du Québec, Institut Nationale de Santé Publique du Québec, Sainte-Anne-de-Bellevue, QC H9X 3R5, Canada.
  • Goyette G; Centre de Recherche du CHUM, Montreal, QC H2X 0A9, Canada.
  • Gendron-Lepage G; Centre de Recherche du CHUM, Montreal, QC H2X 0A9, Canada.
  • Medjahed H; Centre de Recherche du CHUM, Montreal, QC H2X 0A9, Canada.
  • De Serres G; Institut National de Santé Publique du Québec, Quebec, QC H2P 1E2, Canada.
  • Tremblay C; Centre de Recherche du CHUM, Montreal, QC H2X 0A9, Canada; Département de Microbiologie, Infectiologie et Immunologie, Université de Montréal, Montreal, QC H2X 0A9, Canada.
  • Martel-Laferrière V; Centre de Recherche du CHUM, Montreal, QC H2X 0A9, Canada; Département de Microbiologie, Infectiologie et Immunologie, Université de Montréal, Montreal, QC H2X 0A9, Canada.
  • Kaufmann DE; Centre de Recherche du CHUM, Montreal, QC H2X 0A9, Canada; Département de Médecine, Université de Montréal, Montreal, QC H3T 1J4, Canada.
  • Bazin R; Héma-Québec, Affaires Médicales et Innovation, Quebec, QC G1V 5C3, Canada.
  • Prévost J; Centre de Recherche du CHUM, Montreal, QC H2X 0A9, Canada; Département de Microbiologie, Infectiologie et Immunologie, Université de Montréal, Montreal, QC H2X 0A9, Canada.
  • Moreira S; Laboratoire de Santé Publique du Québec, Institut Nationale de Santé Publique du Québec, Sainte-Anne-de-Bellevue, QC H9X 3R5, Canada.
  • Richard J; Centre de Recherche du CHUM, Montreal, QC H2X 0A9, Canada; Département de Microbiologie, Infectiologie et Immunologie, Université de Montréal, Montreal, QC H2X 0A9, Canada. Electronic address: jonathan.richard.1@umontreal.ca.
  • Côté M; Department of Biochemistry, Microbiology and Immunology, Center for Infection, Immunity, and Inflammation, University of Ottawa, Ottawa, ON K1H 8M5, Canada. Electronic address: marceline.cote@uottawa.ca.
  • Finzi A; Centre de Recherche du CHUM, Montreal, QC H2X 0A9, Canada; Département de Microbiologie, Infectiologie et Immunologie, Université de Montréal, Montreal, QC H2X 0A9, Canada; Department of Microbiology and Immunology, McGill University, Montreal, QC H3A 2B4, Canada. Electronic address: andres.finzi@um
Cell Rep ; 38(9): 110429, 2022 03 01.
Article en En | MEDLINE | ID: mdl-35216664
Continuous emergence of SARS-CoV-2 variants of concern (VOCs) is fueling the COVID-19 pandemic. Omicron (B.1.1.529) rapidly spread worldwide. The large number of mutations in its Spike raise concerns about a major antigenic drift that could significantly decrease vaccine efficacy and infection-induced immunity. A long interval between BNT162b2 mRNA doses elicits antibodies that efficiently recognize Spikes from different VOCs. Here, we evaluate the recognition of Omicron Spike by plasma from a cohort of SARS-CoV-2 naive and previously infected individuals who received their BNT162b2 mRNA vaccine 16 weeks apart. Omicron Spike is recognized less efficiently than D614G, Alpha, Beta, Gamma, and Delta Spikes. We compare with plasma activity from participants receiving a short (4 weeks) interval regimen. Plasma from individuals of the long-interval cohort recognize and neutralize better the Omicron Spike compared with those who received a short interval. Whether this difference confers any clinical benefit against Omicron remains unknown.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Esquemas de Inmunización / Anticuerpos Neutralizantes / Glicoproteína de la Espiga del Coronavirus / SARS-CoV-2 / Vacuna BNT162 Tipo de estudio: Etiology_studies / Incidence_studies / Observational_studies / Risk_factors_studies Límite: Adult / Aged / Female / Humans / Male / Middle aged País/Región como asunto: America do norte Idioma: En Revista: Cell Rep Año: 2022 Tipo del documento: Article País de afiliación: Canadá Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Esquemas de Inmunización / Anticuerpos Neutralizantes / Glicoproteína de la Espiga del Coronavirus / SARS-CoV-2 / Vacuna BNT162 Tipo de estudio: Etiology_studies / Incidence_studies / Observational_studies / Risk_factors_studies Límite: Adult / Aged / Female / Humans / Male / Middle aged País/Región como asunto: America do norte Idioma: En Revista: Cell Rep Año: 2022 Tipo del documento: Article País de afiliación: Canadá Pais de publicación: Estados Unidos